All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 17th May 2017, copanlisib (BAY 80-6946), a pan-class I PI3K inhibitor, was granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of R/R FL patients who have received ≥2 previous treatments.
This regulatory submission was based on results of the pivotal CHRONOS-1 phase II trial, which aimed to assess the safety and efficacy of copanlisib in 141 patients with R/R iNHL. Primary results for the whole patient cohort were presented at this year’s American Association for Cancer Research (AACR) annual meeting, which the Lymphoma Hub reported on last month. Data specifically from patients with FL will be presented at this year’s American Society of Clinical Oncology (ASCO) annual meeting in June.
Bayer’s copanlisib has already been awarded Fast Track and Orphan Drug designations by the FDA for R/R FL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox